| Literature DB >> 26462266 |
C Durga Rao1, P P Maiya2, M Ananda Babu3.
Abstract
OBJECTIVE: Infectious and non-infectious causes are associated with increased frequency of bowel movements (IFoBM). But, a viral aetiology to non-diarrhoeal IFoBM (IFoBM-ND) has not been described. Owing to an accidental infection by an echovirus 19 strain, persistent diarrhoea-associated virus, isolated from a child with persistent diarrhoea, DCR experienced persistent IFoBM-ND with an urgency to pass apparently normal stools more than once each day for about 3 months. A follow-up study was undertaken to determine the prevalence of IFoBM-ND, and association of non-polio enteroviruses (NPEVs) with the symptom in infants from birth to 2 years.Entities:
Keywords: ENTERIC INFECTIONS; INFECTIOUS DIARRHOEA; MOTILITY DISORDERS; NEONATAL GUT; SMALL BOWEL MOTILITY
Year: 2015 PMID: 26462266 PMCID: PMC4533327 DOI: 10.1136/bmjgast-2014-000011
Source DB: PubMed Journal: BMJ Open Gastroenterol ISSN: 2054-4774
Figure 1Age-dependent average frequency of non-diarrhoeal bowel movements (BM-ND) in the cohort. The 2-year follow-up duration is divided for convenience into four 6-month periods. The frequency of non-diarrhoeal BM per day during the four successive 6-month periods from birth ranged between 0–16, 0–12, 0–8 and 0–4, respectively.
Figure 2Age-dependent changes in bowel movement (BM) frequencies. BM frequencies were grouped into six categories, 1 in a day (1/D), 2 in a day (2/D), 3–4 in a day (3–4/D), 5–17 in a day, 1 in 2–4 days (1/2–4D) and 1 in 5–10 days (1/5–10D). The per cent proportion of non-diarrhoeal BM of each category in each age group is calculated with reference to the total number of non-diarrhoeal BM of the respective category occurring in all the four age groups.
Analysis of IFoBM-ND episodes in comparison to diarrhoeal episodes
| Subjects, samples, episodes | 0–6 months | 6–12 months | 12–18 months | 18–24 months | Total (%) | |
|---|---|---|---|---|---|---|
| 1 | Cohort children followed (n=140) | 140 | 130 | 112 | 70 | 140 |
| 2 | Total samples | 1724 | 1603 | 1381 | 864 | 5572 |
| 3 | Total OPV-negative samples | 1078 | 1430 | 1268 | 769 | 4545 |
| 4 | Total NPEV-positive samples | 260 | 179 | 135 | 84 | 638/4545 (14.0) |
| 5 | Total NPEV-negative samples | 818 | 1251 | 1133 | 685 | 3907/4545 (86.0) |
| 6 | Total NPEV episodes | 162 | 115 | 76 | 50 | 403/4545 (8.9) |
| 7 | NPEV+ve-acute episodes (%) | 103/162 (63.6) | 83/115 (72.2) | 49/76 (64.5) | 33/50 (66.0) | 268/403 (66.5) |
| Acute diarrhoeal episodes | 19 | 13 | 10 | 6 | 48/403 (11.9) | |
| NPEV-AIFoBM-ND/total NPEV-IFoBM-ND episodes (%) | 25/61 (41.0) | 21/61 (34.4) | 9/61 (14.8) | 6/61 (9.8) | 61/115 (53.0) | |
| NPEV-AIFoBM-ND/total NPEV episodes (%) | 25/162 (15.4) | 21/115 (18.3) | 9/76 (11.8) | 6/50 (12.0) | 61/403 (15.1) | |
| NPEV-acute symptomatic (IFoBM+diarrhoea) | 44 | 34 | 19 | 12 | 109/403 (27.1) | |
| Acute asymptomatic NPEV episodes | 59 | 49 | 30 | 21 | 159/403 (39.5) | |
| 8 | NPEV-positive persistent episodes | 59 | 32 | 27 | 17 | 135 |
| NPEV-positive PD episodes (%) | 7/162 (4.3) | 7/115 (6.1) | 9/76 (11.8) | 2/50) (4.0) | 25/403 (6.2) | |
| NPEV-PIFoBM-ND/total NPEV-PIFoBM-ND (%) | 26*/54 (48.2) | 12/54 (22.2) | 9/54 (16.7) | 7/54 (13.0) | 54/115 (47.0) | |
| NPEV-PIFoBM-ND/total NPEV episodes (%) | 26/162 (16.0) | 12/115 (10.4) | 9/76 (11.8) | 7/50 (14.0) | 54/403 (13.4) | |
| NPEV-persistent symptomatic (PD+PIFoBM-ND) | 33 | 19 | 18 | 9 | 79/403 (19.6) | |
| Persistent asymptomatic NPEV episodes | 26 | 13 | 9 | 8 | 56/403 (13.9) | |
| 9 | Non-NPEV-IFoBM-ND episodes | 15 | 6 | 2 | 1 | 24/139 (17.3) |
| 10 | NPEV-IFoBM-ND/total NPEV-IFoBM-ND (%) | 51/115 (44.4) | 33/115 (28.7) | 18/115 (15.6) | 13/115 (11.3) | 115/403 (28.5) |
| NPEV-IFoBM-ND/total NPEV- +non-NPEV-IFoBM-ND (%) | 51/139 (36.7) | 33/139 (23.7) | 18/139 (12.9) | 13/139 (9.4) | 115/139 (82.7) | |
| Total NPEV-IFoBM-ND/total non-diarrhoeal episodes (%) | 51/330 (15.5) | 33/330 (10.0) | 18/330 (5.5) | 13/330 (3.9) | 115/330 (34.9) | |
| 11 | NPEV diarrhoeal episodes/NPEV infection episodes (%) | 26/162 (16.1) | 20/115 (17.4) | 19/76 (25.0) | 8/50 (16.0) | 73/403 (18.0) |
| 12 | NPEV symptomatic episodes/period (%) | 77/162 (47.5) | 53/115 (46.1) | 37/76 (48.7) | 21/50 (42.0) | 188/403 (46.7) |
| NPEV symptomatic episodes/total NPEV episodes (%) | 77/403 (17.0) | 53/403 (13.2) | 37/403 (9.2) | 21/403 (5.2) | ||
| 13 | NPEV asymptomatic episodes/period (%) | 85/162 (52.5) | 62/115 (53.9) | 39/76 (51.3) | 29/50 (58.0) | 215/403 (53.3) |
| NPEV asymptomatic episodes/total NPEV episodes (%) | 85/403 (21.1) | 62/403 (15.4) | 39/403 (9.7) | 29/40 (6.9) | ||
| NPEV asymptomatic episodes/non-diarrhoeal episodes (%) | 85/330 (25.8) | 62/330 (18.8) | 39/330 (11.8) | 29/330 (8.8) | 215/330 (65.2) | |
| 14 | RV diarrhoea/RV episodes (%) | 16/49 (32.7) | 14/23 (60.9) | 7/15 (46.7) | 5/9 (55.6) | 42/96 (43.7) |
| 15 | NPEV-RV-positive episodes | 15 | 4 | 4 | 2 | 25/4545 (0.5) |
| 16 | NPEV+RV-diarrhoeal episodes/total diarrhoeal episodes (%) | 9/193 (4.6) | 1 (0.5) | 1 (0.5) | 1 (0.5) | 12/193 (6.2) |
| 17 | Diarrhoea due to other agents/total diarrhoea (%) | 25/193 (12.9) | 20/193 (10.3) | 13/193 (6.7) | 8/193 (4.1) | 66/193 (34.2) |
*One PIFoBM-ND episode was of NPEV-RV mixed infection.
Details of diarrhoeal episodes, OPV samples, NPEV-positive and NPEV-negative samples have been described in detail previously.30
AIFoBM, acute increased frequency of bowel movements; IFoBM-ND, non-diarrhoeal IFoBM; NPEV, non-polio enterovirus; OPV, oral polio vaccine; PD, persistent diarrhoea; PIFoBM-ND, persistent IFoBM-ND; RV, rotavirus.
Figure 3Per cent proportion of different non-polio enterovirus (NPEV)-associated symptoms with reference to total NPEV infection episodes in the cohort community during the 2-year follow-up period. Total number of samples, total NPEV-positive episodes, diarrhoeal episodes and oral polio vaccine samples in the follow-up study were described previously30 (IFoBM, increased frequency of bowel movements).
NPEV serotypes associated with acute diarrhoea, PD, AIFoBM, PIFoBM and asymptomatic infections, and the sequence of infections in PIFoBM episodes involving EV, RV and DEC
| EV-serotypes | Strains in acute & PD episodes analysed | Frequency of detection of different NPEV serotypes in 48 independent PIFoBM-ND episodes analysed | AIFoBM-ND episodes analysed | Total IFoBM-ND samples/episodes analysed | Asymptomatic EV episodes analysed | Total EV samples/episodes examined |
|---|---|---|---|---|---|---|
| E1 | 2 | 10 | 20 | 10 | 32 | |
| E2 | 2 | – | 3 | – | 5 | |
| E3 | 2+ | – | 1 | 1 | 1 | 6 |
| E5 | 1 | – | – | – | – | 1 |
| E6 | 5+ | 3 | 16 | 2 | 33 | |
| E7 | 2+ | 2 | 4 | 1 | 15 | |
| E11 | 6+ | 6 | 22 | 8 | 39 | |
| E12 | – | – | – | – | 2 | 2 |
| E13 | 4+ | 1 | 2 | 1 | 9 | |
| E14 | 2+ | 2 | 6 | 2 | 11 | |
| E19 | 3+ | 3 | 9 | 5 | 20 | |
| E20 | 2 | 2 | 4 | 3 | 9 | |
| E21 | – | 1 | 4 | 2 | 6 | |
| E24 | 3+ | 2 | 8 | 1 | 15 | |
| E25 | – | 2 | 5 | 2 | 7 | |
| E30 | 1 | – | – | – | 2 | 3 |
| E32 | 1+ | 2 | 6 | 2 | 10 | |
| E33 | 4+ | 3 | 6 | 2 | 14 | |
| EV75 | 3+ | – | – | – | – | 5 |
| EV76 | – | – | – | – | 1 | 1 |
| EV83 | – | 1 | 2 | 1 | 3 | |
| CVA4 | 1+ | – | – | – | 1 | 3 |
| CVA9 | 1+ | – | 1 | 1 | 1 | 4 |
| CVA13 | 1 | – | – | – | 1 | 2 |
| CVA24 | 1+ | – | 1 | 1 | – | 3 |
| CVB3 | 2 | – | 1 | 1 | 1 | 4 |
| CVB4 | 1+ | 1 | 1 | 1 | 5 | |
| CVB5 | 1+1 | – | – | – | – | 2 |
| OPV1 | 1+ | – | 4 | – | 7 | |
| OPV2 | 1 | – | – | – | – | 1 |
| OPV3 | 1 | – | – | – | – | 1 |
| Total | 54+ | 45 | 53 |
The numbers in each row in each column represent the number of episodes from which the VP1 gene from strains belonging to the particular EV serotype was sequenced. Strains indicated in parenthesis in italic font refer to sequential infections by more than one NPEV serotype or agent in that order and those in normal font refer to monotypic infections. Strains from all the IFoBM-ND and asymptomatic NPEV infection episodes were not examined. Numbers in italic font in the bottom row include some sequentially collected samples during persistent episodes indicating representation of some episodes more than once, and the numbers in parenthesis in normal font in the bottom row indicate actual number of PIFoBM-ND episodes analysed. In the second column, numbers in normal and italic fonts represent samples from acute and persistent diarrhoeal episodes, respectively.
AIFoBM, acute increased frequency of bowel movements; CVA, coxsackievirus A; CVB, coxsackievirus B; DEC, diarrhoeagenic Escherichia coli; E, echovirus; EAEC, enteroaggregative E. coli; EPEC, enteropathogenic E. coli; ETEC, enterotoxigenic E. coli; EV, enterovirus; IFoBM-ND, non-diarrhoeal IFoBM; NPEV, non-polio enterovirus; OPV, oral polio vaccine; PD, persistent diarrhoea; PIFoBM, persistent IFoBM; RV, rotavirus.